February 28, 2019 / 12:13 PM / 24 days ago

Novavax's respiratory infection vaccine fails in late-stage trial

Feb 28 (Reuters) - Novavax Inc said on Thursday its vaccine to prevent RSV infection, a leading cause of a respiratory disease in infants, failed to meet the main goal of a late stage study.

The vaccine failed to prevent lower respiratory tract infection related to RSV, or respiratory syncytial virus, the company said. (Reporting by Manas Mishra in Bengaluru; Editing by Sai Sachin Ravikumar)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below